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Abstract
Biochemical properties of Ras oncoproteins and their transforming ability strongly support a
dominant mechanism of action in tumorigenesis. However, genetic studies unexpectedly
suggested that wild-type (WT) Ras exerts tumor suppressor activity. Expressing oncogenic
NrasG12D in the hematopoietic compartment of mice induces an aggressive myeloproliferative
neoplasm (MPN) that is exacerbated in homozygous mutant animals. Here we show that increased
NrasG12D gene dosage, but not inactivation of WT Nras, underlies the aggressive in vivo behavior
of NrasG12D/G12D hematopoietic cells. Modulating N-RasG12D dosage had discrete effects on
myeloid progenitor growth, signal transduction, and sensitivity to MEK inhibition. Furthermore,
enforced WT N-Ras expression neither suppressed the growth of Nras mutant cells nor inhibited
myeloid transformation by exogenous NrasG12D. Importantly NRAS expression in increased in
human cancer cell lines with NRAS mutations. These data have therapeutic implications and
support reconsidering the proposed tumor suppressor activity of WT Ras in other cancers.
Significance—Understanding mechanisms of Ras-induced transformation and adaptive cellular
responses are fundamental questions. The observation that oncogenic Nras lacks tumor suppressor
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activity while increased dosage strongly modulates cell growth and alters sensitivity to MEK
inhibition suggests new therapeutic opportunities in cancer.
Introduction
Ras genes encode ubiquitously expressed proteins (N-Ras, H-Ras, K-Ras4A and K-Ras4B)
that cycle between active GTP-bound and inactive GDP-bound conformations (Ras-GTP
and Ras-GDP)1. Ras-GTP levels are regulated by the competing activities of guanine
nucleotide exchange factors and GTPase activating proteins (GAPs), which enhance
intrinsic Ras GTPase activity. Proteins encoded by RAS oncogenes, which accumulate in
the GTP-bound state due to defective intrinsic GTP hydrolysis and resistance to GAPs, are
exceedingly difficult targets for anti-cancer drug discovery due to their structural and
biochemical properties1.
Despite compelling evidence that oncogenic Ras proteins have dominant gain-of-function
actions in cellular transformation, genetic studies in mice surprisingly suggested that wild-
type (WT) Ras exerts tumor suppressor activity in some cancers with oncogenic Ras
mutations2-5. However, mechanistic data regarding how normal Ras might antagonize
oncogenic signaling are lacking.
Endogenous expression of NrasG12D induces a myeloproliferative neoplasm (MPN) in Mx1-
Cre, NrasG12D/+ mice that faithfully models human chronic and juvenile myelomonocytic
leukemia (CMML and JMML)4,6,7. Hematologic disease is greatly accelerated in
homozygous NrasG12D mutant mice (Mx1-Cre, NrasG12D/G12D)8,9. We deployed a
conditional Nras mutant allele to assess the relative contributions of NrasG12D oncogene
dosage and tumor suppression by WT Nras in myeloid transformation. We find that elevated
NrasG12D expression drives myeloid transformation in vivo and strongly modulates cell
growth, Ras signaling, and response to a targeted inhibitor in vitro. Consistent with these
data, somatic uniparental disomy underlies loss of the WT allele in primary acute myeloid
leukemia (AML) cells with NrasG12D mutations, resulting in normal-to-increased Nras
expression. Finally, NRAS expression is significantly elevated in human cancer cell lines
with NRAS mutations while KRAS expression is reduced, with a reciprocal pattern seen in
cell lines with KRAS mutations.
Results
We generated a Cre-dependent conditional Nras allele (Nras2lox2) by and performed
intercrosses to produce hemizygous (Mx1-Cre; LSL-NrasG12D/2lox2), heterozygous (Mx1-
Cre; LSL-NrasG12D/+), and homozygous (Mx1-Cre; LSL-NrasG12D/G12D) littermates on a
C57Bl/6 strain background (Supplemental Fig. S1A). Use of this conditional Nras2lox2 allele
avoids potential confounding consequences of eliminating WT Nras expression throughout
development, and allowed us to simultaneously activate NrasG12D expression and inactivate
WT Nras in the hematopoietic compartment after birth4. Efficient recombination of both
conditional Nras alleles with loss of expression was observed two weeks later (Supplemental
Figs. S1B, S1C). Western blot analysis confirmed that N-Ras protein levels are reduced in
the bone marrow of hemizygous Nras mutant mice (Fig. 1A), which we hereafter refer to as
NrasG12D/-.
Consistent with recent reports8,9, ~20% of Mx1-Cre; NrasG12D/G12D mice died prematurely
from T lineage acute lymphoblastic leukemia (T-ALL) (Supplemental Fig. S2A). Surviving
animals of all three Nras genotypes were euthanized at 6 months of age. All NrasG12D/G12D
mice had overt MPN, which was characterized by leukocytosis with elevated blood
neutrophil counts, splenomegaly, and anemia (Fig. 1B and Supplemental Fig. S2B). By
contrast, hematologic parameters were normal in age-matched Mx1-Cre; NrasG12D/+ and
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Mx1-Cre; NrasG12D/- mice (Fig. 1B and Supplemental Fig. S2B). Flow cytometric analysis
revealed increased numbers of immature monocytic (Mac-1+, Gr-1lo) cells in the
hematopoietic tissues of NrasG12D/G12D mice, which is also observed in Nf1 and Kras
mutant mice with MPN7 (Fig. 1C). This population was not expanded in hemizygous or
heterozygous Nras mutant mice.
We grew colony forming unit granulocyte macrophage (CFU-GM) progenitors to assess the
cell intrinsic effects of NrasG12D gene dosage and the consequences of inactivating WT
Nras. Somatic NRAS mutations are highly prevalent in JMML and CMML, and CFU-GM
progenitors from patients with these aggressive cancers are hypersensitive to granulocyte
macrophage colony stimulating factor (GM-CSF)7. Similarly, NrasG12D/G12D bone marrow
cells demonstrate cytokine-independent CFU-GM growth and pronounced GM-CSF
hypersensitivity (Fig. 1D)8,9. In striking contrast, CFU-GM from Mx1-Cre; NrasG12D/- and
Mx1-Cre; NrasG12D/+ mice displayed normal cytokine responses (Fig 1D). Phospho-flow
cytometric analysis of Lin-/cKit+/CD105-/CD34+ bone marrow cells, which are highly
enriched for myeloid progenitors (Supplemental Fig. S2C), revealed elevated basal levels of
phosphorylated ERK (pERK) and enhanced responsiveness to GM-CSF in NrasG12D/G12D
cells compared to heterozygous and hemizygous NrasG12D mutant cells (Fig. 1E). In
summary, phenotypic, functional, and biochemical analyses of age and strain-matched mice
indicate that WT Nras lacks tumor suppressor activity in the hematopoietic lineage.
To ask if exogenous WT Nras expression might antagonize the abnormal growth of
NrasG12D/G12D cells, we infected Mx1-Cre; NrasG12D/G12D bone marrow with murine stem
cell virus (MSCV) vectors encoding N-terminal green fluorescent protein (GFP) fused to
WT N-Ras (N-RasWT), WT K-Ras (K-RasWT), or dominant negative N-Ras (N-RasN17)9.
After sorting to isolate GFP-positive (GFP+) cells, CFU-GM colony growth was assayed in
the presence of GM-CSF. Mx1-Cre; NrasG12D/G12D bone marrow formed significantly more
CFU-GM colonies than heterozygous or hemizygous Nras cells (Fig. 2A). Expressing N-
RasWT or K-RasWT had no effect on CFU-GM colony growth from NrasG12D/G12D bone
marrow, while dominant negative N-RasN17 reduced growth by greater than two-fold (Fig.
2A).
To further investigate if WT N-Ras interferes with oncogenic N-RasG12D-induced myeloid
transformation, we infected WT fetal liver cells with MSCV vectors expressing N-terminal
mCherry-tagged N-RasG12D in combination with GFP, GFP-tagged N-RasWT, or GFP-
tagged K-RasWT. Flow cytometry and Western blotting revealed an equivalent increase in
Ras protein levels in co-transduced cells (Figs. 2B,C). Importantly, neither WT Ras isoform
suppressed the aberrant pattern of cytokine-independent CFU-GM progenitor growth
induced by exogenous N-RasG12D expression (Fig. 2D).
We next assessed the functional and biochemical consequences of varying Nras oncogene
dosage by infecting WT fetal hematopoietic cells with viruses encoding GFP-tagged N-
RasG12D and sorting for different levels of GFP expression (Fig. 3A). As expected,
increasing GFP intensity correlated with higher N-Ras protein levels (Fig. 3B). Progenitors
expressing the highest levels of N-RasG12D demonstrated cytokine-independent CFU-GM
colony growth with a threshold level of expression required for myeloid transformation
(Figs. 3B,C).
We also interrogated Ras signaling in transduced GFP+ bone marrow-derived macrophages
that were first deprived of cytokines and serum, then stimulated with GM-CSF10. Under
these conditions, Akt, Erk, and S6 were not phosphorylated in starved macrophages infected
with the empty pMIG vector, and these cells responded robustly to GM-CSF stimulation
(Fig. 3D). Macrophages expressing low levels of N-RasG12D showed a modest increase in
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basal pAkt, pErk, and pS6, which were augmented by cytokine stimulation. By contrast,
starved cells expressing the highest levels of N-RasG12D exhibited a further increase in basal
levels of all three phospho-proteins, but were unresponsive to GM-CSF (Fig. 3D). Thus, Akt
and ERK activation are uncoupled from cytokine stimulation in primary myeloid cells
expressing high levels of oncogenic N-Ras.
Treatment with the potent and selective MEK inhibitor PD0325901 restores a normal pattern
of hematopoiesis in Kras and Nf1 mutant mice with MPN11,12. We therefore asked if
endogenous NrasG12D gene dosage influences the sensitivity of bone marrow-derived
macrophages to MEK inhibition. Macrophages grown directly from the bone marrows of
Mx1-Cre; NrasG12D/+ and Mx1-Cre; NrasG12D/G12D mice expanded to a similar extent in the
presence of a saturating concentration macrophage colony stimulating factor (Fig. 3E).
Remarkably, low concentrations of PD0325901 selectively reduced the growth of
homozygous Nras mutant macrophages (Fig. 3E) despite similar basal levels of ERK
activation and sensitivity to inhibition by MEK inhibitor treatment (Supplemental Fig. S3A,
B).
NrasG12D expression cooperated with the MOL4070LTR retrovirus to efficiently induce
AML in Mx1-Cre; NrasG12D/+ mice that recapitulates morphologic and genetic features of
human Nras mutant AMLs4. Somatic loss of the WT Nras allele occurs in many of these
leukemias (Supplemental Fig. S4A)4. Importantly, however, real-time quantitative PCR
analysis showed that Nras expression is normal or increased in AML blasts (Fig. 4A).
Interestingly, Kras expression was reduced to levels below that in WT bone marrow
(Supplemental Fig. S4B). Consistent with these data, Western blot analysis revealed
elevated N-Ras protein levels in AML blasts, including NrasG12D leukemias with somatic
loss of the normal Nras allele (Fig. 4B). We performed fluorescence in situ hybridization
(FISH) to investigate the mechanism underlying somatic Nras inactivation in leukemias with
loss of constitutional heterozygosity (LOH), and also used Taqman PCR to assess Nras copy
number. Both analyses supported somatic uniparental disomy (UPD) with duplication of the
oncogenic NrasG12D allele as the genetic basis underlying loss of the WT Nras allele in
leukemias with LOH (Figs. 4C, D). Together, these studies indicate that genetic and
transcriptional mechanisms converge to augment oncogenic N-RasG12D expression in AML.
To address the broad relevance of increased RAS oncogene expression in human cancer, we
queried NRAS/KRAS mutational status and corresponding expression data across 957
cancer cell lines from different tissues13. Cancer cell lines with NRAS mutations showed a
highly significant increase in NRAS expression (Fig. 4E). Similarly, lines with KRAS
mutations expressed more KRAS transcript on average. Furthermore, cancer cell lines with
NRAS mutations showed a significant reduction in KRAS expression, while those with
KRAS mutations down-regulated NRAS (Fig. 4E). Similar trends were observed when the
hematopoietic cell lines in this large collection were analyzed separately (Supplemental Fig.
S5A). Gene expression data from a well-annotated collection of human AMLs revealed
elevated NRAS expression compared to normal CD34+ progenitors in leukemias with and
without Nras mutations (Supplemental Fig. S5B).
Discussion
LOH is common in human cancer and classically represents a genetic “second hit” that
results in homozygous inactivation of tumor suppressor genes (TSGs) that negatively
regulate cell growth through diverse mechanisms. Given this, the finding of frequent
somatic oncogenic Ras mutations and loss of the corresponding WT allele in mouse cancers
induced by chemical carcinogenesis raised the possibility that normal Ras proteins might
also restrain malignant growth2. Indeed, subsequent experiments demonstrating that germ
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line inactivation of one Ras allele greatly increased the incidence and biologic
aggressiveness of genotoxin-induced skin and lung carcinoma supported this idea5,14. While
provocative, it has proven difficult to reconcile these genetic data with the dominant
transforming ability of oncogenic Ras proteins and their biochemical properties. Although
normal Ras genes may function to suppress tumorigenesis in some cell lineages, loss of the
normal Ras allele may reflect selective pressure for cancers to increase oncogene dosage as
they evolve. This idea is compatible with data showing that spontaneous transformation in
primary Hras mutant fibroblasts is associated with amplification of the mutant allele15, and
with frequent copy number gains, mutant allele specific imbalance, and over-expression of
oncogenic KRAS in human cancer cell lines16. Interestingly, oncogenic Hras amplification
is an early event in murine skin carcinogenesis models and may be associated with somatic
UPD2,17.
Somatic NRAS mutations are common in hematologic malignancies, and Mx1-Cre;
NrasG12D mice provide a tractable and genetically accurate system for interrogating the
putative TSG activity of WT Nras in early (MPN) and late (AML) stage cancers that does
not rely on chemical carcinogenesis. Our extensive genetic and functional analysis indicates
that WT Nras lacks tumor suppressor activity in vitro and in vivo, and identifies increased
oncogene expression as the major “driver” of aberrant growth. Consistent with these data,
oncogenic NRAS mutations with UPD have been reported in human AML18. A JMML with
an NRAS mutation that acquired UPD after evolution to AML suggests a role of increased
oncogenic NRAS dosage in disease progression19. The pattern of Ras gene expression in
murine Nras mutant leukemias and in human cancer cell lines with oncogenic RAS
mutations also supports the existence of selective pressure to amplify oncogenic signaling
by increasing oncoprotein levels while simultaneously down-regulating normal Ras.
The dominant role of mutant Ras amplification is consistent with data showing that
expressing oncogenic K-RasG12D and N-RasG12D from their endogenous genetic loci results
in remarkably little activation of canonical effectors in primary cells, which likely reflects
the inhibitory effects of potent cellular feedback responses20,21. The dramatic effects of
modulating N-RasG12D protein levels on basal activation of Ras effectors and on cytokine
responses further suggest that cancer cells must titrate an “optimal” level of pathway
activation to overcome negative feedback inhibition without evoking cell cycle arrest or
senescence.
The idea that normal Ras proteins might antagonize the transforming properties of their
oncogenic counterparts suggested potential therapeutic strategies. While this possibility
remains viable in tissues such as skin and lung where normal RAS genes are likely to
function as tumor suppressors, our data strongly argue that restoring or enhancing normal
Ras expression will be ineffective in leukemias with oncogenic NRAS mutations. They also
support revisiting this general question in other cancers, particularly given the broad pattern
of elevated NRAS or KRAS expression in human cancer cell lines with mutations in each
gene. Furthermore, as cancer cells amplify oncogenic signaling to optimize growth, they
may become more dependent upon (“addicted to”) these activated pathways, which might be
exploited therapeutically. The enhanced dependence of NrasG12D/G12D macrophages on
MEK supports this idea. Similarly, somatic UPD is common in AML with oncogenic FLT3
mutations and is associated with resistance to conventional anti-cancer agents22. However,
these leukemias are more sensitive to FLT3 inhibitors than AMLs without UPD23. Thus,
selective pressure favoring the outgrowth of clones with increased oncogenic RAS gene
expression may also render them more susceptible to inhibitors of critical effector pathways.
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Mouse strains and pathologic analysis
Nras2lox2 mice were generated by inserting loxP sites onto each side of exon 2 of the
endogenous Nras locus in V26.2 C57BL/6 embryonic stem cells 24. A Frt-flanked Neo
resistance cassette was also inserted into intron 1 (Supplemental Fig. S1A). After germline
transmission of the targeted allele, the Neo resistance cassette was removed by crossing to
an Flp deleter strain (Jackson Laboratory, Bar Harbor, ME). Mx1-Cre, NrasG12D mice were
intercrossed with Nras2lox2 mice to generate Mx1-Cre, NrasG12D/G12D, Mx1-Cre
NrasG12D/+, and Mx1-Cre NrasG12D/2lox2 mice. All mice received a single intraperitoneal
injection of poly-I/poly-C (250 μg) at 3 weeks of age to active Mx1-Cre expression 4. Mice
were euthanized at 6 months of age to assess disease. Pathologic examinations were
performed as previously described4.
Hematopoietic progenitor assays and flow cytometry
Hematopoietic progenitor assays and flow cytometric analyses were performed as
previously described 4,10
Retroviral transduction
NrasWT, KrasWT, NrasN17, and NrasG12D alleles containing either N-terminal green
fluorescent protein (GFP) or N terminal mCherry markers were cloned into the murine stem
cell virus (MSCV) vector with expression driven by the internal ribosomal entry site (IRES).
Retrovirally transduced E14.5 fetal liver cells from C57Bl/6 mice were sorted to isolate
GFP-positive cells, which were plated in methylcellulose medium to assess colony-forming
unit-granulocyte/macrophage (CFU-GM) growth as described previously4.
Biochemistry
Biochemical analyses were performed on cultured macrophages that were differentiated
from transduced GFP-positive (GFP+) fetal liver cells in 50 ng/mL macrophage colony
stimulating factor (M-CSF) as described previously10. Quantitative effects of PD0325901 on
macrophage ERK signaling were determined by imaging and quantifying blots on an
Odyssey imager
FISH Analysis
A labeled bacterial artificial chromosome (BAC) probe containing the mouse Nras gene
(RP23- 280E21; 150 kb) was labeled with 5-(3-aminoallyl)-dUTP by nick-translation,
followed by chemical labeling with amine-reactive Alexa fluor 488 using the Ares DNA
labeling kit. An 8 kb genomic probe containing the Nras gene was labeled with biotin-dUTP
by nick translation and detected with streptavidin conjugated with Alexa fluor 568. FISH
was performed as described previously25. Cells were counterstained with 4,6 diamidino-2-
phenylindole-dihydrochloride. A minimum of 200 interphase nuclei and 10 metaphase cells
were scored for each sample.
RNA purification and quantitative PCR analysis
RNA purification and quantitative PCR analyses of primary AML cells that were generated
by infecting NrasG12D/+ mice with the MOL4070LTR retrovirus were performed as
previously described4.
Xu et al. Page 6














Genomic DNA from Nras mutant AMLs was purified using a Qiagen kit. A total of 10 ng of
DNA was used as a template for quantitative PCR experiments. The sequence for murine
transferrin receptor (mTfrc) was used to normalize total amounts of DNA. The premixed
probe and primer assay mixture used to quantify total amounts of genomic Nras were
purchased from Applied Biosystems.
Macrophage proliferation assay
8×105 bone marrow derived-macrophages from Mx1-Cre, NrasG12D/G12D or Mx1-Cre,
NrasG12D/+ mice were plated in triplicate in 12 well plates in the presence of 10 ng/mL M-
CSF and varying doses of PD0325901. Total numbers of viable cells were counted using the
Beckman Coulter Vi-Cell XR at day 5.
Gene expression profiling of cell line and AML
NRAS and KRAS expression in cancer cell lines was extracted from gene-centric RMA-
normalized mRNA expression data downloaded from Cancer Cell Line Encyclopedia13.
KRAS and NRAS mutational status was determined by hybrid capture and Oncomap assays.
P values were calculated by two-tailed student’s t test assuming unequal variance. To further
examine NRAS and KRAS expression of human leukemia, we performed microarray-based
gene expression profiling data of pediatric AML and normal CD34+ samples generated
using Affymetrix U133A microarrays (Affymetrix, Santa Clara, CA) according to the
manufacturer’s instructions, with data processed using MAS5 normalization and log2
transformation26. This cohort comprised 108 samples including CD34+ bone marrow cells
(N=4), and included 74 without an NRAS mutation and 30 with a mutation. Primary data are
available through http://www.ncbi.nlm.nih.gov/geo/ accessions GSE43176 (AML samples)
and GSE33315 (CD34+ bone marrow).
No experiments were performed on any cell lines to generate this data.
All mouse experiments were approved by IACUC.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Dominant Effects of NrasG12D Dosage in Hematologic Disease
(A) Western blot analysis of bone marrow lysates from 6 week-old mice shows reduced total
N-Ras protein levels in hemizygous NrasG12D mice. (B) Spleen weights and white blood cell
(WBC) counts of 6 month-old heterozygous (n=38), hemizygous (n=32), and homozygous
(n=20) NrasG12D mice. (C) Representative flow cytometric analysis of bone marrow and
spleen specimens from all 3 genotypes with the myeloid markers Gr-1 and Mac-1. The
percentage of immature monocytic (Gr-1lo, Mac-1hi) cells is shown on each panel. (D) CFU-
GM colony growth from NrasG12D/+ (black line), NrasG12D/- (blue line), and NrasG12D/G12D
(red line) bone marrow cells in over a range of GM-CSF concentrations (n= 5-7 per
genotype). Note that only NrasG12D/G12D cells demonstrate cytokine-independent progenitor
growth. (E) Flow cytometric analysis of basal ERK phosphorylation in Lin- c-Kit+ CD105-
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CD34+ bone marrow cells from 3 month-old mice and response to GM-CSF stimulation (10
ng/mL for 15 min). The vertical black line indicates basal pERK levels in WT cells.
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Figure 2. Wild-type Ras Does Not Antagonize Myeloid Transformation by NrasG12D
(A) Left panel. CFU-GM progenitor growth from NrasG12D/+, NrasG12D/-, and
NrasG12D/G12D (n=6 from each genotype) bone marrow cells in the presence of 1 ng/mL
GM-CSF (*** p<0.0001). Right panel. Bone marrow from NrasG12D/G12D mice was
infected with MSCV vectors encoding GFP-tagged WT N-Ras (N-RasWT), WT K-Ras (K-
RasWT), or a dominant negative N-Ras protein (N-RasN17). After sorting to isolative GFP+
cells, CFU-GM colonies were grown in the presence of 1ng/mL GM-CSF. The data are from
three independent experiments (* p=0.0135). (B) WT E14.5 fetal liver cells were co-
transduced with MSCV vectors expressing mCherry-N-RasG12D and either GFP only
(pMIG), GFP-N-RasWT, or GFP-K-RasWT. Flow cytometic analyses indicate equivalent
numbers of PE-Texas Red (mCherry) and FITC (GFP) double positive cells. The GFP
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fluorescence is higher in cells expressing GFP only. (C) Immunoblot analysis demonstrates
that cells co-transduced with oncogenic N-RasG12D and WT N-Ras or WT K-Ras express
more total Ras than control cells transduced with N-RasG12D and an “empty” MIG vector.
(D) CFU-GM colony growth from sorted cells expressing both GFP and mCherry over a
range of GM-CSF concentrations. N-RasG12D transforms ~40% of myeloid progenitors to
cytokine independent growth, and co-expressing WT N-Ras or K-Ras does not alter this
phenotype.
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Figure 3. Oncogenic NrasG12D Signaling is Dosage Dependent
(A) Subpopulations of WT E14.5 fetal livers cells were infected with a virus expressing
GFP-N-RasG12D and isolated by sorting based on the level GFP fluorescence (L-low, M1-
low medium, M2-high medium, H-high). (B) Immunoblot analysis of macrophages grown
from fetal liver cells in panel A indicates that N-Ras levels correlate with GFP positivity.
(C) CFU-GM colony growth from fetal liver cells expressing L, M1, M2, and H levels of
GFP-N-RasG12D. (D) The macrophages shown in panel B were starved overnight, then
stimulated with 10 ng/mL of GM-CSF for 15 or 60 min. Levels of phosphorylated Erk, Akt
and S6 were assessed by Western blotting. (E) Growth of cultured bone marrow derived-
macrophages from 26 week-old Mx1-Cre, NrasG12D/G12D (n = 4) and Mx1-Cre, NrasG12D/+
(n = 5) mice. Left panel. Total cell numbers after 5 days in the absence of PD0325901. Right
panel. Percentage reduction in cell numbers in cells exposed to 0.01, 0.1, and 1 nM of
PD0325901 for 5 days. Asterisks denote significant differences between NrasG12D/G12D and
Mx1-Cre, NrasG12D/+ (* p=0.0425, ** p=0.0076).
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Figure 4. N-Ras Expression in AMLs from NrasG12D/+ Mice
(A) Quantitative real-time PCR of Nras mRNA expression in WT bone marrow and primary
NrasG12D AMLs with and without LOH (NrasG12D leukemias with loss of or a marked
reduction in the WT allele are shown in red and AMLs that retain the WT allele are in
black). (B) Western blot of NrasG12D AMLs shows that N-Ras proteins levels are equivalent
to or higher than in WT mouse bone marrow. (C) FISH analysis of metaphase and
interphase cells from representative AMLs with (#6730; left panel) and without (#6768;
right panel) LOH. Arrowheads identify a fused signal from both BAC probe RP23-280E21
and the smaller Nras probe. Hybridizing with the larger BAC clone uniformly revealed
signals on both chromosomal homologs in all 5 NrasG12D AMLs. Equal percentages of cells
demonstrated one or two hybridization signals (shown here) with the much smaller Nras-
specific probe from AMLs with and without LOH. (D) Nras DNA copy number is normal or
increased in NrasG12D AMLs with and without LOH as assessed by Taqman quantitative
PCR. (E) NRAS and KRAS expression in 957 human cancer cell lines with NRAS
mutations (n = 56), KRAS mutations (n = 173), or no RAS mutation (n = 728) (**
p=0.0018) (***p=7.7E-16).
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